These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 1361478

  • 1. HER-2/neu expression: a major prognostic factor in endometrial cancer.
    Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC.
    Gynecol Oncol; 1992 Nov; 47(2):179-85. PubMed ID: 1361478
    [Abstract] [Full Text] [Related]

  • 2. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
    Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Berchuck A.
    Cancer; 1994 May 01; 73(9):2380-5. PubMed ID: 7909491
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma.
    Hamel NW, Sebo TJ, Wilson TO, Keeney GL, Roche PC, Suman VJ, Hu TC, Podratz KC.
    Gynecol Oncol; 1996 Aug 01; 62(2):192-8. PubMed ID: 8751548
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer.
    Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz C, Gitsch G.
    Cancer Lett; 1996 Jan 02; 98(2):151-5. PubMed ID: 8556702
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
    Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS.
    Mod Pathol; 1997 Aug 02; 10(8):823-31. PubMed ID: 9267826
    [Abstract] [Full Text] [Related]

  • 8. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW.
    Gynecol Oncol; 1994 Apr 02; 53(1):84-92. PubMed ID: 7909788
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression.
    Coronado PJ, Vidart JA, Lopez-asenjo JA, Fasero M, Furio-bacete V, Magrina J, Escudero M.
    Eur J Obstet Gynecol Reprod Biol; 2001 Sep 02; 98(1):103-8. PubMed ID: 11516808
    [Abstract] [Full Text] [Related]

  • 12. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
    Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.
    Cancer Res; 1995 Dec 01; 55(23):5693-8. PubMed ID: 7585656
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
    Baak JP, Chin D, van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS.
    Lab Invest; 1991 Feb 01; 64(2):215-23. PubMed ID: 1671789
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.
    Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Iglehart JD.
    Ann Surg; 1994 Apr 01; 219(4):332-41. PubMed ID: 7909221
    [Abstract] [Full Text] [Related]

  • 18. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
    Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB.
    Int J Oncol; 2008 Feb 01; 32(2):307-16. PubMed ID: 18202752
    [Abstract] [Full Text] [Related]

  • 19. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
    Schneider J, Rubio MP, Barbazán MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS.
    J Natl Cancer Inst; 1994 Jun 01; 86(11):850-5. PubMed ID: 7910219
    [Abstract] [Full Text] [Related]

  • 20. The role of the HER-2/neu oncogene in gynecologic cancers.
    Cirisano FD, Karlan BY.
    J Soc Gynecol Investig; 1996 Jun 01; 3(3):99-105. PubMed ID: 8796816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.